Objective: Patients with adeno/adenosquamous carcinoma may have a poorer prognosis than patients with squamous cell carcinoma. Radiotherapy and concurrent chemoradiotherapy are used as adjuvant therapies for cervical cancer, regardless of the histological subtype. The aim of this study was to investigate the prognostic outcome of adjuvant therapy for patients with adeno/ adenosquamous carcinoma with pathological risk factors. Methods: The medical records of 135 patients with stage IB-IIB cervical cancer with squamous cell carcinoma or adeno/adenosquamous carcinoma who underwent primary surgery followed by adjuvant therapy were retrospectively reviewed. Patients with a pathologically confirmed bulky tumor (≥4 cm), nodal metastasis and/or parametrium invasion were included in the study. Results: The median follow-up period was 48 (1-132) months. Of the 135 patients, 90 with squamous cell carcinoma and 23 with adeno/adenosquamous carcinoma were treated with adjuvant radiotherapy and concurrent chemoradiotherapy (SCC-RT/CCRT and AC-RT/CCRT groups), and 22 with adeno/adenosquamous carcinoma were treated with adjuvant systemic chemotherapy (AC-CT group). There were no significant differences in clinicopathological factors between the SCC-RT/CCRT and AC-RT/CCRT groups and between the AC-RT/CCRT and AC-CT groups. Progression-free survival was significantly shorter in the AC-RT/CCRT group compared to the SCC-RT/CCRT group (P = 0.002). Adeno/adenosquamous carcinoma histology and multiple lymph node metastasis were independent prognostic factors for shorter progression-free survival in patients treated with adjuvant radiotherapy and concurrent chemoradiotherapy. Progression-free survival was also significantly shorter in the AC-RT/CCRT group compared to the AC-CT group (P = 0.026). Conclusions: Adjuvant radiotherapy and concurrent chemoradiotherapy may be less effective for patients with adeno/adenosquamous carcinoma than for those with squamous cell carcinoma. Adjuvant systemic chemotherapy may be beneficial for adeno/adenosquamous carcinoma and further studies are warranted.
Introduction
Radical hysterectomy and pelvic lymphadenectomy (RH) with definitive radiotherapy (RT) or concurrent chemoradiotherapy (CCRT) is recommended in treatment guidelines for early stage cervical cancer (1) (2) (3) . After primary surgery, adjuvant CCRT is also recommended for patients with pelvic node metastasis, positive surgical margin, parametrium invasion or other risk factors (i.e. large primary tumor, stromal invasion and/or lymph-vascular space invasion) (1) (2) (3) (4) (5) . Clinical trials have shown that adjuvant RT/CCRT is effective for both squamous cell carcinoma (SCC) and adeno/ adenosquamous carcinoma (AC) (4, 5) . Therefore, adjuvant RT/ CCRT is widely recommended for cervical AC and SCC, according to pathological risk factors.
Several studies have shown a poorer prognosis for AC due to frequent lymph node involvement, distant organ metastasis, or lower sensitivity to RT, compared to SCC (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) . Therefore, we hypothesized that RT/CCRT focused on the pelvic area might not be equally suitable for patients with SCC and AC with pathological risk factors after radical surgery. To investigate the prognosis of adjuvant RT/ CCRT in AC compared to SCC, we retrospectively reviewed outcomes for 113 patients with AC or SCC with pathological risk factors who underwent radical surgery followed by adjuvant RT/ CCRT, which is standard therapy for such patients (primary study).
A questionnaire study in Japan showed that 33 of 166 institutions in the Japanese Gynecologic Oncology group use adjuvant chemotherapy (CT) for patients with risk factors (17) , but a comparison of the efficacy of adjuvant CT and RT/CCRT for patients with AC has not been conducted. Therefore, we added this comparison through a retrospective review of outcomes in 45 AC cases with pathological risk factors treated with radical surgery followed by adjuvant CT or RT/CCRT (additional study).
Patients and methods

Patients
We retrospectively reviewed the medical records of 135 patients with FIGO IB-IIB cervical cancer who met the following inclusion criteria and were treated at four hospitals affiliated with The Jikei University School of Medicine between 2001 and 2010. Inclusion criteria were: (i) FIGO stage IB-IIB, (ii) primary radical surgery, (iii) AC or SCC histologically classified using the World Health Organization (WHO) staging system for tumors of the uterine cervix, (iv) one or more pathological risk factors of a bulky tumor (>4 cm), parametrium invasion, and pelvic node metastasis, and (v) postoperative adjuvant RT, CCRT or CT. Cases with a positive surgical margin and those treated with neoadjuvant CT were excluded.
Adjuvant therapy
The choice of adjuvant RT, CCRT or CT was determined using the institutional treatment policy for cervical cancer with pathological risk factors after radical surgery. RT and CCRT were performed at a dose of 45-50 Gy using whole pelvic external beams with X-rays of ≥6 MV in four field box beams, in fractions of 1.8-2 Gy given daily five times per week for five weeks, with or without intracavitary brachytherapy. For CCRT, weekly intravenous cisplatin (40 mg/m 2 , 5-6 cycles) was administered concurrent with RT. CT regimens and the number of cycles were determined by each institution.
Follow-up and analysis
After treatment, all patients underwent regular follow-up consisting of clinical checkups such as a pelvic examination, ultrasonography scan and periodic computed tomography or magnetic resonance imaging. Survival information was available for all patients. Overall survival (OS) was assessed from the date of initial surgery to the time of death or last contact. Progression-free survival (PFS) was defined as the time from initial surgery until progression of disease or last contact.
Statistical analysis
In the primary study, univariate and multivariate analyses were used to compare the prognosis by histological subtype in patients treated with adjuvant RT/CCRT. Subgroup analysis was performed for patients treated with adjuvant CCRT because this treatment has been shown to give a more favorable prognosis than RT for AC (5) .
In the additional study, univariate analysis was used to investigate the prognostic benefit of adjuvant therapy for AC, compared with adjuvant CT and adjuvant RT/CCRT. Subgroup analysis for patients treated with adjuvant CT and adjuvant CCRT was also performed.
All comparisons between histological subtypes in the primary study and between adjuvant treatment methods in the additional study were performed by chi-square-test, except for age, for which a Student's t-test was used. OS and PFS curves were calculated using the Kaplan-Meier method and the difference between groups was assessed by log-rank test. A multiple Cox regression model was used to explore the impact of specific prognostic factors on OS and PFS. All P values are two sided and P < 0.05 was considered to be significant. All statistical analysis was performed with EZR (Saitama Medical Centre, Jichi Medical University; http://www.jichi.ac.jp/ saitama-sct/SaitamaHP.files/statmedOSX.html, Kanda, 2012), which is a graphical interface for R (The R foundation for Statistical Computing. Vienna, Austria, ver. 3.2.2). EZR is a modified version of R commander (ver. 2.1-7) that was designed for functions that are frequently used in biostatistics.
Results
Patient characteristics
Of the 135 patients, there were 68 and 22 with SCC treated with adjuvant CCRT and RT, respectively (SCC-RT/CCRT group), 18 and 5 with AC treated with adjuvant CCRT and RT, respectively (AC-RT/CCRT group), and 22 with AC treated with adjuvant CT (AC-CT group). The characteristics in each group are summarized in Table 1 , including age, FIGO stage, tumor diameter, lymph node metastasis, parametrium invasion, histological subtype and adjuvant treatment. There were no significant differences in these factors between the SCC-RT/CCRT and AC-RT/CCRT groups and between the AC-RT/CCRT and AC-CT groups. Primary study: survival and prognostic factors in patients treated with adjuvant RT/CCRT
The median follow-up period was 48 months (1-132) in all patients, 50 months (1-132) in the SCC-RT/CCRT group, and 42 months (6-121) in the AC-RT/CCRT group. PFS was significantly shorter in the AC-RT/CCRT group (P = 0.002, Fig. 1A ) and OS tended to be shorter in this group, although the difference was not significant (P = 0.178, Fig. 1B ).
In multivariate analysis using a Cox regression model (Table 2) , AC histology (compared to SCC histology) was a predictor of worse PFS (P = 0.007; hazard ratio (HR), 2.877; 95% confidential interval (CI), 1.331-6.215), and 2 or more positive lymph node metastasis were a predictor of worse OS (P = 0.008; HR, 8.431; 95% CI, 1.756-40.490) and PFS (P = 0.001>; HR, 5.859; 95% CI, 2.172-15.810). Thus, AC histology and multiple lymph node metastasis are independent prognostic factors for PFS, and multiple lymph node metastasis is an independent prognostic factor for OS in patients with pathological risk factors after radical surgery followed by adjuvant RT/CCRT. The prognosis of patients who received adjuvant CCRT was also assessed in subgroups of patients with AC and SCC. PFS was significantly shorter in patients with AC (P = 0.007, Fig. 2A ), whereas there was no significant difference in OS (P = 0.582, Fig. 2B ). Multivariate analysis indicated that AC histology (P = 0.009; HR, 3.125; 95% CI, 1.333-7.692) and positive lymph node metastasis (P = 0.012; HR, 4.098; 95% CI, 1.355-12.400) were predictors of worse PFS.
Additional study: survival after adjuvant treatment for patients with AC
The efficacies of adjuvant CT and adjuvant RT/CCRT were retrospectively investigated in 45 patients with AC. The median follow-up period was 45 months (6-124) in all patients, 36 months (6-120) in the AC-RT/CCRT group, and 46 months (7-124) in the AC-CT group. PFS was significantly shorter in the AC-RT/CCRT group (P = 0.026, Fig. 3A ). There was no significant difference in OS between the groups (P = 0.245, Fig. 3B ). In subgroup analysis, a significant difference in PFS was detected between patients treated with adjuvant CCRT and CT (P = 0.014, data not shown). Multivariate analysis to identify independent prognostic factors could not be performed due to the small sample size. Notably, in patients in the AC-CT group with lymph node metastasis, there was no recurrence or death, even in those with multiple positive nodes.
Metastatic site according to adjuvant treatment and histology
The primary sites of recurrence were investigated in the SCC-RT/ CCRT, AC-RT/CCRT and AC-CT groups to compare the features of the treatment methods (Table 3 ). There were no statistical differences among the groups, but distant metastasis was more frequent in the AC-RT/CCRT group than in the SCC-RT/CCRT group, and less frequent in the AC-CT group than in the AC-RT/CCRT group.
Discussion
Two clinical observations were made in this report. First, we showed the relative ineffectiveness of adjuvant RT/CCRT as standard adjuvant therapy for patients with stage IB-IIB AC with pathological risk factors after radical surgery. Second, adjuvant CT might be beneficial for these patients. First, we showed the relative ineffectiveness of adjuvant RT/ CCRT as standard adjuvant therapy for patients with stage IB-IIB AC with pathological risk factors after radical surgery. Adjuvant RT/CCRT is currently recommended for FIGO stage IB-IIB patients with pathological risk factors, regardless of histological subtype. The result of the GOG92 trial showed that patients with AC who received adjuvant RT had a lower recurrence rate than those treated with surgery alone (4). Additionally, the SWOG 8797 trial, which included 21% AC patients, showed that adjuvant CCRT improves PFS and OS for patients with histologically confirmed nodal metastasis, parametrium invasion or a positive surgical margin (5). A subgroup analysis in patients who received RT showed that patients with AC had worse PFS compared to those with SCC, suggesting lower sensitivity of AC to RT, but adding concurrent CT to RT compensated for this weakness (5) . Based on these results, adjuvant RT/CCRT is widely recommended for cervical AC and SCC. However, most patients in the primary study in this report received adjuvant CCRT and a subgroup analysis in patients treated with CCRT showed worse PFS for AC histology. Mabuchi et al. also found a worse prognosis for patients with AC with pathological risk factors after radical surgery followed by adjuvant CCRT (18) for four cycles. The total dose is higher and the treatment period of concurrent CT is longer in SWOG 8797 than in our study. Therefore, the higher dose of CT might have contributed to improvement of the prognosis of AC patients in the SWOG 8797. Further, we speculate that the systemic effect of CT played an important role, rather than enhancing the effect of RT. Second, our results showed that adjuvant CT might be promising for stage IB-IIB AC with pathological risk factors after radical surgery. The results of our primary study and those in Mabuchi et al. suggest that it is necessary to search for more effective adjuvant therapy than RT/CCRT. AC histology may be more likely to spread to a distant area, compared to SCC. Eifel et al. showed that distant metastasis in Stage II/III AC patients who received initial RT was higher than that in SCC patients (9). Drescher et al. reported that paraaortic and paratracheal metastasis, peritoneal dissemination, ascites and hydrothorax are more frequent in AC than in SCC, based on autopsy findings (10) . Our results support these findings, since the distant metastatic rates were 20.0% and 34.9% in the SCC-RT/CCRT and AC-RT/CCRT groups, respectively (Table 3) . Therefore, systemic treatment is better for AC histology, and our results suggest that adjuvant CT might be more effective than RT/ CCRT for patients with AC. Several other studies have also shown that adjuvant CT might have some advantages over RT/CCRT regarding treatment-related complications (19, 20) .
The CT regimen for cervical cancer is relatively well investigated in metastatic or recurrent cervical cancer. Based on the GOG169 and GOG204 studies, combination CT using cisplatin and paclitaxel is superior to cisplatin alone or another drug combination with cisplatin (21, 22) . The Japan Clinical Oncology Group (JCOG) 0505 study showed non-inferiority of carboplatin and paclitaxel compared to a cisplatin and paclitaxel regimen in terms of OS for stage IVB, persistent or recurrent cervical cancer (23) . Recently, the GOG240 study showed that addition of bevacizumab to cytotoxic CT improves OS in patients with metastatic and recurrent cervical cancer (24) . However, the conclusions of these studies are not necessarily applicable for patients with AC, given the limited numbers of AC cases included in the studies. In the present additional study, most patients (18 of 22) were treated with platinum-containing combination CT, and our results suggest that this CT, such as paclitaxel and carboplatin, might have positive effects on AC as adjuvant therapy. Determination of the appropriate regimen of cytotoxic CT with a molecular targeted drug as adjuvant therapy for AC requires further prospective studies.
There are several limitations in this study. First, the retrospective design prevented elimination of potential confounding biases in the analysis, such as a selection bias for the treatment method in each case. Second, although there was no significant difference in patient characteristics between the AC-RT/CCRT and AC-CT groups, the rates of patients with lymph node metastasis and parametrium invasion were slightly higher in the AC-RT/CCRT group (Table 1 ). In addition, we could not perform multivariate analysis to confirm the prognostic benefit of adjuvant CT for AC due to the small number of patients. Third, the regimen for adjuvant CT was not standardized, and various regimens were used according to the institutional policy at the time of treatment of each patient. Finally, our results showed a prognostic difference between groups only for PFS, due to the short follow-up period. These confounding factors could be eliminated in a prospective randomized controlled trial.
In conclusion, this study suggests that adjuvant RT/CCRT might be less effective for AC than for SCC, and that adjuvant CT using a platinum-containing drug might be more effective than adjuvant RT/CCRT for AC. To determine the best adjuvant therapy for patients with AC with pathological risk factors after radical surgery, large-scale retrospective studies followed by randomized controlled trials are needed to compare the efficacies of adjuvant RT/CCRT and CT in these patients.
